Coral Laboratories Peer Comparison

BSE: 524506

₹568.05

₹23.05 (4.23%)

As on 30-Sep-2026IST

Market cap

₹203 Cr

Revenue (TTM)

₹97 Cr

P/E Ratio

10.6

P/B Ratio

0.9

Div. Yield

0.4 %

Edit

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	203	20,590	20,453	17,730	16,511
Revenue (₹ Cr)	97	2,287	1,682	2,570	3,230
Net Profit (₹ Cr)	19.21	678.07	273.51	735.15	666.92
Net Margin (%)	18.00	28.10	16.19	26.88	20.60
RoE (%)	8.98	19.73	11.15	19.16	18.75
Price to Earnings	10.57	30.95	68.79	24.12	25.64
Price-To-Book	0.95	5.61	7.61	4.02	4.09

Income Statement (₹ Cr)

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	96.70	2,287.33	1,682.47	2,569.77	3,229.67
Total Income	106.70	2,413.29	1,689.83	2,735.39	3,237.12
Total Expenditure	78.18	1,490.75	1,203.91	1,628.14	2,090.06
EBITDA	18.52	796.58	478.55	941.63	1,139.61
Depreciation	2.35	78.10	126.01	57.58	281.06
EBIT	16.17	718.48	352.55	884.05	858.55
Interest	0.15	0.88	52.11	7.69	190.64
Other Income	10.00	125.96	7.37	165.62	7.45
Exceptional Items	0.31	0.00	12.16	-49.16	-17.24
Profit before Tax	26.34	843.56	319.96	992.82	658.12
Provision for Tax	7.13	165.49	46.45	257.67	-8.80
Profit after Tax	19.21	678.07	273.51	735.15	666.92

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	209.12	3,586.42	2,591.20	4,202.90	3,902.67
Minority Interest	0.00	-12.71	0.00	0.00	-21.81
Non-Current Liabilities	4.24	28.74	266.35	91.50	1,392.75
Current Liabilities	27.31	385.94	848.06	627.48	2,077.10
Total Liabilities	229.46	3,207.85	3,310.68	4,911.11	6,865.52

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	61.30	1,291.22	2,525.44	770.28	5,617.77
Current Assets	176.97	2,585.66	1,109.77	3,803.22	1,539.85
Total Assets	229.46	3,207.85	3,310.68	4,911.11	6,865.52
Total Debt*	3.56	0.55	586.37	2.50	2,421.66
Net Current Assets	149.66	2,199.72	261.71	3,175.74	-537.25
Contingent Liabilities	--	0.64	76.22	363.79	51.96

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	-1.22	432.37	132.27	659.75	1,065.01
Cash Flow from Investing Activities	-0.15	-334.73	-199.13	-71.34	-79.97
Cash from Financing Activities	2.71	-38.32	62.65	-205.34	-881.32
Net Cash Inflow / Outflow	1.33	59.32	-4.21	383.07	103.72

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	17.04	26.22	6.95	26.21	13.59
ROE (%)	8.98	19.73	11.15	19.16	18.75
ROA (%)	8.17	18.69	7.80	14.95	9.26
EBIT Margin (%)	16.72	31.41	20.95	34.40	26.58
Net Margin (%)	18.00	28.10	16.19	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	-5.35	15.01	27.91	10.69	9.59
EBIT Growth (%)	2.90	18.45	58.32	24.14	16.84
Net Profit Growth (%)	7.21	19.61	149.56	-9.09	62.68
EPS Growth (%)	2.59	17.73	-3.57	14.40	67.41
Book Value Growth (%)	13.36	23.77	30.63	17.30	10.19

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	10.70	30.95	72.97	22.98	24.99
Price / Book Value	0.95	5.61	7.61	4.02	4.09
Dividend Yield (%)	0.35	0.30	0.06	1.94	0.00
EV/EBITDA	5.35	24.58	44.02	15.53	16.46
Market Cap (₹ Cr)	250.59	15,219.80	6,484.12	18,318.10	19,292.77

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.00	0.07	0.00	0.24
Short term debt to equity ratio	0.02	0.00	0.13	0.00	0.14
Current Ratio	6.48	6.70	1.31	6.06	0.74
Quick Ratio	5.73	5.59	0.88	5.31	0.53
Interest Coverage	182.66	959.59	7.14	130.11	4.45

	Coral Laboratories	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	30.43	36.10	30.84	7.07	21.07
Asset Turnover	0.41	0.63	0.48	0.52	0.45
Receivable days	98.13	110.70	118.15	29.10	54.06
Inventory Days	39.72	65.86	98.29	69.53	32.16
Payable days	102.34	105.88	128.16	76.77	140.91
Cash Conversion Cycle	35.50	70.68	88.28	21.86	-54.69

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.